{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:20Z","timestamp":1791414140311,"version":"4.3.3"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T00:00:00Z","timestamp":1464825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anaerobe"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.anaerobe.2016.05.015","type":"journal-article","created":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T23:09:31Z","timestamp":1464908971000},"page":"58-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection"],"prefix":"10.1016","volume":"41","author":[{"given":"Michael","family":"Kaleko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Andrew","family":"Bristol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Parsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Widmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul","family":"Tzipori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poorani","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrti","family":"Koski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kokai-Kun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anaerobe.2016.05.015_bib1","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.bbadis.2014.05.023","article-title":"Rapidly expanding knowledge on the role of the gut microbiome in health and disease","volume":"1842","author":"Cenit","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrmicro2974","article-title":"The gut microbiota\u2013masters of host development and physiology","volume":"11","author":"Sommer","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1756283X13482996","article-title":"Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ","volume":"6","author":"Guinane","year":"2013","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nri3430","article-title":"Role of the gut microbiota in immunity and inflammatory disease","volume":"13","author":"Kamada","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2014.11.012","article-title":"The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies","volume":"135","author":"West","year":"2015","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib6","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1053\/j.gastro.2014.01.059","article-title":"Role of the intestinal microbiota in resistance to colonization by Clostridium difficile","volume":"146","author":"Britton","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib7","first-page":"333","article-title":"Antibiotic therapy and Clostridium difficile infection - primum non nocere - first do no harm","volume":"8","author":"Crowther","year":"2015","journal-title":"Infect. Drug Resist"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib8","first-page":"335","article-title":"Influence of cephalosporins III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy","volume":"21","author":"Guggenbichler","year":"1986","journal-title":"Padiatr. Padol."},{"issue":"Suppl 1","key":"10.1016\/j.anaerobe.2016.05.015_bib9","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1007\/BF01644235","article-title":"The influence of third-generation cephalosporins on the aerobic intestinal flora","volume":"13","author":"Guggenbichler","year":"1985","journal-title":"Infection"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib10","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.amjmed.2006.03.012","article-title":"Antimicrobial resistance in gram-positive bacteria","volume":"119","author":"Rice","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib11","series-title":"Audits of Acute Care Hospital Antibiotic Utilization","author":"Arlington Medical Resources","year":"2014"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib12","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s10096-012-1603-0","article-title":"Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case-control study","volume":"31","author":"Vesteinsdottir","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2146\/ajhp140645","article-title":"Clostridium difficile infection: a brief update on emerging therapies","volume":"72","author":"Goldberg","year":"2015","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib14","doi-asserted-by":"crossref","first-page":"h5149","DOI":"10.1136\/bmj.h5149","article-title":"Faecal transplants","volume":"351","author":"Spector","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv005","article-title":"Fecal microbiota transplant: benefits and risks","volume":"2","author":"Weil","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.mib.2005.08.016","article-title":"Beta-lactam antibiotic resistance: a current structural perspective","volume":"8","author":"Wilke","year":"2005","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib17","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/nar\/9.11.2577","article-title":"Penicillinase from Bacillus licheniformis: nucleotide sequence of the gene and implications for the biosynthesis of a secretory protein in a Gram-positive bacterium","volume":"9","author":"Neugebauer","year":"1981","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib18","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1128\/AAC.00853-08","article-title":"P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin","volume":"53","author":"Tarkkanen","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib19","first-page":"838","article-title":"IPSAT P1A, a class A beta-lactamase therapy for the prevention of penicillin-induced disruption to the intestinal microflora","volume":"10","author":"Pitout","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib20","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/jac\/dkn298","article-title":"Orally administered beta-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile","volume":"62","author":"Stiefel","year":"2008","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib21","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1086\/379153","article-title":"Oral administration of beta-lactamase preserves colonization resistance of piperacillin-treated mice","volume":"188","author":"Stiefel","year":"2003","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/jac\/dkg095","article-title":"Enzymic degradation of a beta-lactam antibiotic, ampicillin, in the gut: a novel treatment modality","volume":"51","author":"Harmoinen","year":"2003","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib23","first-page":"S67","article-title":"A\u00a0novel therapy in prevention of antibiotic-induced changes in faecal microflora","volume":"19","author":"Harmoinen","year":"2002","journal-title":"Int. J. Antimicro Agents"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1128\/AAC.48.1.75-79.2004","article-title":"Orally administered targeted recombinant beta-lactamase prevents ampicillin-induced selective pressure on the gut microbiota: a novel approach to reducing antimicrobial resistance","volume":"48","author":"Harmoinen","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib25","unstructured":"A Study of SYN-004 for the prevention of C. diff in patients with a LRTI. Clinicaltrials.gov, NCT02563106. accessed 16.05.16."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/1091581815623236","article-title":"Nonclinical safety assessment of SYN-004: an oral b-lactamase for the protection of the gut microbiome from disruption by biliary-excreted, intravenously administered antibiotics","volume":"35","author":"Kokai-Kun","year":"2016","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib27","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1042\/bj0261406","article-title":"Studies on plant amylases: the effect of starch concentration upon the velocity of hydrolysis by the amylase of germinated barley","volume":"26","author":"Hanes","year":"1932","journal-title":"Biochem. J."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib28","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1128\/JCM.15.5.954-958.1982","article-title":"In\u00a0vitro evaluation of CENTA, a new beta-lactamase-susceptible chromogenic cephalosporin reagent","volume":"15","author":"Jones","year":"1982","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4161\/gmic.23867","article-title":"A\u00a0pig model of the human gastrointestinal tract","volume":"4","author":"Zhang","year":"2014","journal-title":"Gut Microbes"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CDLI.1.4.450-463.1994","article-title":"Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin","volume":"1","author":"Tzipori","year":"1994","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib31","doi-asserted-by":"crossref","first-page":"e97699","DOI":"10.1371\/journal.pone.0097699","article-title":"Microbial community profiling of human saliva using shotgun metagenomic sequencing","volume":"9","author":"Hasan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib32","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1126\/science.1254529","article-title":"Longitudinal analysis of microbial interaction between humans and the indoor environment","volume":"345","author":"Lax","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1471-2105-11-367","article-title":"A\u00a0flexible R package for nonnegative matrix factorization","volume":"11","author":"Gaujoux","year":"2010","journal-title":"BMC Bioinforma."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib34","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1073\/pnas.082099299","article-title":"Diagnosis of multiple cancer types by shrunken centroids of gene expression","volume":"99","author":"Tibshirani","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Pt 1","key":"10.1016\/j.anaerobe.2016.05.015_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1042\/bj2760269","article-title":"A\u00a0standard numbering scheme for the class A beta-lactamases","volume":"276","author":"Ambler","year":"1991","journal-title":"Biochem. J."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib36","series-title":"SYN-004, a Class A b-Lactamase Therapy for the Prevention of Antibiotic-induced Disruption of Intestinal Microflora._ID Week, Philadelphia, PA","author":"Kaleko","year":"2014"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib37","series-title":"SYN-004, a Clinical Stage Oral Beta-lactamase Therapy, Protects the Intestinal Microflora from Antibiotic-mediated Damage in Humanized Pigs","author":"Connelly","year":"2015"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib38","series-title":"A\u00a0Clinical Stage Oral Beta-lactamase Therapy Prevents Antibiotic-mediated Damage of the Gut Microbiome","author":"Connelly","year":"2015"},{"issue":"Supp.","key":"10.1016\/j.anaerobe.2016.05.015_bib39","first-page":"28","article-title":"Methanogens in human health and disease","volume":"1","author":"Pimentel","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/19490976.2014.997612","article-title":"Alteration of the fecal microbiota and serum metabolite profiles in dogs with idiopathic inflammatory bowel disease","volume":"6","author":"Minamoto","year":"2015","journal-title":"Gut Microbes"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib41","doi-asserted-by":"crossref","first-page":"e94699","DOI":"10.1371\/journal.pone.0094699","article-title":"Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease","volume":"9","author":"Rossi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib42","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jac\/dkt477","article-title":"Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis","volume":"69","author":"Slimings","year":"2014","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib43","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/jac\/dkh285","article-title":"Long-term surveillance of cefotaxime and pipercillin-taxobactam prescribing and incidence of Clostridium difficile Diarrhoea","volume":"54","author":"Wilcox","year":"2004","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/jac\/dkh127","article-title":"Increase in the rate of nosocomial clostridium difficile-associated diarrhea during shortages of piperacillin-taxobactam and piperacillin","volume":"53","author":"Alston","year":"2004","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib45","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1128\/AAC.00642-15","article-title":"Risk factors for acquisition and loss of Clostridium difficile colonization in hospitalized patients","volume":"59","author":"Dubberke","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib46","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1128\/AAC.49.12.5190-5191.2005","article-title":"Orally administered recombinant metallo-beta-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice","volume":"49","author":"Stiefel","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib47","series-title":"Clinical Evaluation of SYN-004, An Oral Beta-lactamase Therapy for the Prevention of Antibiotic-induced Disruption of Intestinal Microflora","author":"Sliman","year":"2015"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib48","first-page":"41","article-title":"A\u00a0novel strategy to protect the gut microbiome from the deleterious effects of residual IV \u03b2-lactam antibiotics","volume":"1","author":"Kokai-Kun","year":"2015","journal-title":"J.\u00a0Int. Soc. Microbiota"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib49","article-title":"Nonclinical safety assessment of SYN-004: an oral \u03b2-Lactamase for the protection of the gut microbiome form disruption by biliary-excreted, intravenously-administered antibiotics","author":"Kokai-Kun","year":"2016","journal-title":"J.\u00a0Toxicol."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib50","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/cid\/cir301","article-title":"Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection","volume":"53","author":"Stevens","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib51","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejps.2010.06.018","article-title":"Removal of residual colonic ciprofloxacin in the rat by activated charcoal entrapped within zinc-pectinate beads","volume":"41","author":"Khoder","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib52","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1128\/AAC.06402-11","article-title":"Correlation between fecal concentrations of ciprofloxacin and fecal counts of resistant enterobacteriaceae in piglets treated with ciprofloxacin: toward new means to control the spread of resistance?","volume":"56","author":"Nguyen","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib53","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2125.2005.02357.x","article-title":"Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males","volume":"59","author":"Stass","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.anaerobe.2016.05.015_bib54","series-title":"Development of Therapeutic Agents that Protect the Colonic Microflora from All Beta-lactam Antibiotics for the Prevention of Clostridium difficile Infection","author":"Connelly","year":"2015"},{"key":"10.1016\/j.anaerobe.2016.05.015_bib55","series-title":"P4A, a Novel Oral Beta-lactamase for the Prevention of Cephalosporin-induced C.\u00a0difficile Infection","author":"Kaleko","year":"2014"}],"container-title":["Anaerobe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1075996416300683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1075996416300683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T14:58:16Z","timestamp":1600700296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1075996416300683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":55,"alternative-id":["S1075996416300683"],"URL":"https:\/\/doi.org\/10.1016\/j.anaerobe.2016.05.015","relation":{},"ISSN":["1075-9964"],"issn-type":[{"value":"1075-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection","name":"articletitle","label":"Article Title"},{"value":"Anaerobe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anaerobe.2016.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}